AFMD vs. ONCY, QTTB, ETON, BTAI, CMRX, PMVP, HOOK, YS, SPRO, and IFRX
Should you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Oncolytics Biotech (ONCY), Q32 Bio (QTTB), Eton Pharmaceuticals (ETON), BioXcel Therapeutics (BTAI), Chimerix (CMRX), PMV Pharmaceuticals (PMVP), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.
Oncolytics Biotech (NASDAQ:ONCY) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Oncolytics Biotech presently has a consensus price target of $4.00, suggesting a potential upside of 266.97%. Affimed has a consensus price target of $45.00, suggesting a potential upside of 794.63%. Given Oncolytics Biotech's higher possible upside, analysts plainly believe Affimed is more favorable than Oncolytics Biotech.
Oncolytics Biotech has higher earnings, but lower revenue than Affimed. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Affimed had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Affimed and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.30 beat Affimed's score of 0.00 indicating that Affimed is being referred to more favorably in the news media.
6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by company insiders. Comparatively, 3.8% of Affimed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Affimed received 278 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 68.16% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.
Oncolytics Biotech has a net margin of 0.00% compared to Oncolytics Biotech's net margin of -1,280.27%. Affimed's return on equity of -105.97% beat Oncolytics Biotech's return on equity.
Summary
Affimed beats Oncolytics Biotech on 11 of the 16 factors compared between the two stocks.
Get Affimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
